Savings Reminder

Early Registration Discounts
are Ending May 31st
» View pricing and saving details

Keynote and Featured Presentations

FDA Perspective on Novel Monoclonal Antibody Development Pathways
Kathleen A. Clouse, Ph.D., Director, Division of Monoclonal Antibodies OBP, CDER, US FDA

Protein Engineering with an Expanded Genetic Code
Peter G. Schultz, Ph.D., Professor of Chemistry, The Scripps Research Institute; Founding Director, California Institute for Biomedical Research

Antibody-Drug Conjugates: Current and Future Developments
Hans-Peter Gerber, Ph.D., Executive Director, BioConjugates Discovery and Development, Oncology Research, Pfizer Inc.

Challenges and Opportunities in Developing Scaffold Therapeutics in an Antibody World
Manuel Baca, Ph.D., Fellow, Antibody Discovery & Protein Engineering, MedImmune, LLC

Optimization and Safety of Transfer'rin Bispecifics across the Blood-Brain Barrier
Mark S. Dennis, Principal Scientist, Antibody Engineering, Genentech, Inc.

Bonus! Additional Programming & Networking Opportunities

Attend IBC's co-located
Bioconjugates: From Targets to Therpeutics
at no additional charge!

» View Agenda

What's New This Year?

See what we have added to the Summit for 2013!

Special Discounted Hotel Rate

Special Discounted Hotel Rate Available Until June 4, 2013. To book your room, call 800-468-3533 and mention that you are an IBC attendee at this event.

Testimonials

Read what past attendee's had to say...

For eight years running, IBC's Next Generation Protein Therapeutics Summit has been the industry's most innovative and comprehensive conference for sharing best practices and new ideas to accelerate the discovery, engineering and development of alternative scaffolds and novel protein therapeutics, and this year is no exception.

No other conference on the market consistently brings together world-renowned academic scientists and top industry speakers from diverse disciplines to explore the complexities and find solutions to the unique challenges of protein therapeutic drug development.

Cross-fertilization of new ideas from different fields is often the key to success in drug development and this year's conference features over 85% new speakers and content including three new conference themes.

"This was by far the best conference on therapeutic proteins over the last 7 years. Well done, superb program!" - Fredrik Frejd, Senior Scientist, Affibody, Sweden

Below is just a sample of the exciting new science you will hear by attending:

• Beyond Antibodies

  • Challenges and Opportunities in Developing Scaffold Therapeutics in an Antibody World - MedImmune
  • Multi-Specific DARPins Enabling Novel Therapeutic Concepts - Molecular Partners

• Creative Protein Engineering & Design

  • Human Therapeutic Enzymes for Cancer Therapy via Systemic Amino Acid Depletion - University of Texas
  • Use of Mirror Proteins to Treat Ocular and Lung Diseases - Reflexion Pharmaceuticals

• Accessing Difficult & Intracellular Targets

  • Controlling Intracellular Regulatory Networks with Synthetic Binding Proteins - University of Chicago
  • Stabilized Receptors to Generate Therapeutic Antibodies and Proteins to GPCR Targets - Heptares Therapeutics

• Bispecifics & Genetic Fusions

  • FynomAbs: Bispecific Antibodies with Tailored Architecture - Covagen
  • Targeting of HER2 Receptor with Bispecific DARPin Agents - University of Zurich

• Targeting Strategies & Protein Delivery

  • Crossing the Plasma Membrane with a Delivery Platform Based on Anthrax Lethal Toxin - MIT
  • Optimization and Safety of Transfer'rin Bispecifics across the Blood-Brain Barrier - Genentech

• Exploiting the Immune System for Cancer Therapy

  • BiTEs: Engaging the Cytolytic Power of Polyclonal T cells to Eliminate Tumors - Amgen
  • TandAb technology enables the recruitment of T and NK effector cells - Affimed

Please join us this June at the beautiful Hotel del Coronado near San Diego for this information-packed conference. This exciting event provides you with new ideas and practical strategies for protein therapeutic design and development that you can take home right away and apply in your own laboratory.

Who Should Attend:

These two conferences have been developed for scientists, managers and directors working in Discovery/R&D, Chemistry/ Conjugation, Biochemistry, Protein and Antibody Engineering and Biotherapeutic Development.

"The depth and breadth of the presentations was fantastic covering all aspects of the "Beyond Antibody" landscape from discovery to the clinic" - Michelle Schaeffer, Scientist II, Zyngenia